NR1H4 and Hepatic steatosis: Convincing evidence is provided by a series of studies from the Gonzalez group showing that the intestinal farnesoid X receptor (FXR) promotes ceramide synthesis in the gut, leading to systemic increases in ceramide content that can trigger liver steatosis and systemic metabolic defects [219–221].